Wilmington Savings Fund Society FSB Buys 26,091 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Wilmington Savings Fund Society FSB grew its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 945.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 28,850 shares of the company's stock after purchasing an additional 26,091 shares during the quarter. Wilmington Savings Fund Society FSB's holdings in Teva Pharmaceutical Industries were worth $636,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. UMB Bank n.a. lifted its stake in shares of Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock valued at $44,000 after acquiring an additional 2,067 shares during the period. Smithfield Trust Co lifted its stake in shares of Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock valued at $50,000 after acquiring an additional 980 shares during the period. Claro Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at $52,000. Ameliora Wealth Management Ltd. acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at $66,000. Finally, Venturi Wealth Management LLC acquired a new position in Teva Pharmaceutical Industries in the third quarter valued at about $60,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Wall Street Analyst Weigh In

TEVA has been the topic of several analyst reports. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a research note on Monday, October 21st. UBS Group cut their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. StockNews.com lowered Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, December 18th. Piper Sandler increased their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. Finally, Barclays cut their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.57.

Teva Pharmaceutical Industries Stock Down 2.4 %

Shares of NYSE:TEVA traded down $0.40 during mid-day trading on Friday, reaching $16.24. 12,463,268 shares of the stock were exchanged, compared to its average volume of 12,918,501. The company has a quick ratio of 0.61, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The stock's 50 day simple moving average is $19.98 and its 200-day simple moving average is $18.49. The company has a market cap of $18.39 billion, a P/E ratio of -11.20, a P/E/G ratio of 1.39 and a beta of 0.71. Teva Pharmaceutical Industries Limited has a one year low of $12.51 and a one year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities research analysts predict that Teva Pharmaceutical Industries Limited will post 2.62 EPS for the current year.

Insider Activity

In other news, Director Roberto Mignone sold 286,000 shares of the firm's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares of the company's stock, valued at $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares of the company's stock, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.55% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.